shares of amylyx pharmaceuticals were down at midday on friday after the biopharmaceutical company said its treatment for amytrophic lateral sclerosis also known as lou gehrigs disease has received a negative opinion from european union regulators the stock was down 72 to 2302 at 1212 pm et shares of the cambridge massbased company are down 38 this year amylyx said that the european medicines agencys committee for medicinal products for human use adopted a negative opinion of its application for the conditional marketing authorization of its als treatment amx0035 under the trade name albrioza in may amylyx said it was aware that the committee was trending toward a negative opinion on amx0035